Related Experiment Video
Updated: Dec 16, 2025

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
Published on: August 22, 2017
Fluorescence spectroscopy for determination of dapagliflozin in pure form and its tablets formulation; Application to
Mahmoud A Omar1, Hytham M Ahmed2, Hany A Batakoushy2
1Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medinah, Saudi Arabia; Department of Analytical Chemistry, Faculty of Pharmacy, Minia University, Egypt.
Abstract:
A new, valid method was developed for quantitative spectrofluorimetric analysis of dapagliflozin (DGF) in its pure form and its commercially available tablets (Farxiga®). The proposed analytical method based on measurement of fluorescence intensity for DGF at 303 nm after excitation at 278 nm. Various experimental parameters influencing the fluorescence of DGF were examined to produce the optimal conditions. DGF was successively assayed in concentration range of (100-1000 ng mL-1) with lower detection limit (LOD) of 26.49 and quantitation limit (LOQ) was 79.48 ng mL-1. The suggested method was validated according to ICH guidelines for the estimation of DGF in its pure form and its new dosage form with percent recovery of 100.43 ± 1.15. The proposed method was adapted to examine DGF in content uniformity testing according to United States Pharmacopeia guidelines. This method can be used in routine analysis of DGF in quality control lab.
Related Concept Videos
Drug Dissolution: Requirements and Profile Comparison
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Flame Photometry: Lab
Clinically Relevant Drug Product Specifications: Methods of Establishment
Fluorescence and Phosphorescence: Instrumentation
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

